Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 13/20 | 0.60 |
| ▸ | CA2 | P00918 | 13/20 | 0.60 |
| ▸ | CA1 | P00915 | 12/20 | 0.60 |
| ▸ | CA12 | O43570 | 11/20 | 0.60 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25783041 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL15247399 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL12935270 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL13464528 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL7146506 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL2723141 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL185606 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL2736530 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL18391019 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA | |
| SCHEMBL14923179 | 1.00 | CA9 (0.60) | CA9CA2CA1CA12OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118961-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | CA9 356/4885CA2 1493/4885CA1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.